Theravance Biopharma Inc [NASDAQ: TBPH] loss 0.00% or 0.0 points to close at $7.83 with a heavy trading volume of 3903639 shares.
The daily chart for TBPH points out that the company has recorded -11.22% loss over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 370.87K shares, TBPH reached to a volume of 3903639 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Theravance Biopharma Inc [TBPH]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TBPH shares is $13.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TBPH stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Theravance Biopharma Inc shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on August 06, 2024. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on April 12, 2024, representing the official price target for Theravance Biopharma Inc stock.
The Average True Range (ATR) for Theravance Biopharma Inc is set at 0.48, with the Price to Sales ratio for TBPH stock in the period of the last 12 months amounting to 6.14. The Price to Book ratio for the last quarter was 1.86, with the Price to Cash per share for the same quarter was set at 1.98.
Trading performance analysis for TBPH stock
Theravance Biopharma Inc [TBPH] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.55. With this latest performance, TBPH shares dropped by -12.22% in over the last four-week period, additionally sinking by -11.22% over the last 6 months – not to mention a drop of -20.35% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TBPH stock in for the last two-week period is set at 27.29, with the RSI for the last a single of trading hit 18.07, and the three-weeks RSI is set at 33.43 for Theravance Biopharma Inc [TBPH]. The present Moving Average for the last 50 days of trading for this stock 9.04, while it was recorded at 8.98 for the last single week of trading, and 9.48 for the last 200 days.
Theravance Biopharma Inc [TBPH]: A deeper dive into fundamental analysis
Theravance Biopharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.74 and a Current Ratio set at 5.20.
An analysis of Institutional ownership at Theravance Biopharma Inc [TBPH]
The top three institutional holders of TBPH stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in TBPH stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in TBPH stock with ownership which is approximately 5.1238%.
